Long-term peritoneal dialysis causes morphologic and functional changes in the peritoneal membrane. Although mesothelial-mesenchymal transition of peritoneal mesothelial cells is a key process leading to peritoneal fibrosis, and bioincompatible peritoneal dialysis solutions (glucose, glucose degradation products, and advanced glycation end products or a combination) are responsible for altering mesothelial cell function and proliferation, mechanisms underlying these processes remain largely unclear. Peritoneal fibrosis has 2 cooperative parts, the fibrosis process itself and the inflammation. The link between these 2 processes is frequently bidirectional, with each one inducing the other. This review outlines our current understanding about the definition and pathophysiology of peritoneal fibrosis, recent studies on key fibrogenic molecular machinery in peritoneal fibrosis, such as the role of transforming growth factor-β/Smads, transforming growth factor-β β/Smad independent pathways, and noncoding RNAs. The diagnosis of peritoneal fibrosis, including effluent biomarkers and the histopathology of a peritoneal biopsy, which is the gold standard for demonstrating peritoneal fibrosis, is introduced in detail. Several interventions for peritoneal fibrosis based on biomarkers, cytology, histology, functional studies, and antagonists are presented in this review. Recent experimental trials in animal models, including pharmacology and gene therapy, which could offer novel insights into the treatment of peritoneal fibrosis in the near future, are also discussed in depth.

Lupus is no longer an unknown chameleon of medicine. Significant progress has been made on unraveling the pathogenesis of lupus and lupus nephritis, and how to treat the disease. Here we provide an update on the pathophysiology of lupus and its related kidney disease, consider areas of controversy in disease management, and discuss the unmet needs of lupus nephritis and how to address these needs. We focus on rethinking how innovative therapies for lupus nephritis should be evaluated and evolving strategies to more efficiently mitigate irreversible nephron loss in patients with lupus nephritis.

Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that disproportionately affects nonwhites and those in lower socioeconomic groups. This review discusses recent data on the incidence, prevalence, and outcomes of patients with lupus nephritis with a focus on low-income US Medicaid patients. We also review recent guidelines on diagnosis, treatment, and screening for new onset and relapses of lupus nephritis. Finally, we discuss the management of lupus nephritis from a rheumatologist’s perspective, including vigilance for the common adverse events related to disease and treatment, and we review prevention and new treatment strategies.

Este webinar reconocerà los factores de riesgo de progresión de la ERC etapa 4, definirà las metas de tratamiento y valorarà el inicio planificado de diálisis

The webinar will help you understand the role of mycophenolate for induction and maintenance and the role of rituximab for induction. It will make you aware of the current treatments being trialled and be able to describe some limitations of the current evidence base.

This presentation was given by Richard Wainford from the Whitaker Cardiovascular Institute's Department of Pharmacology and Experimental Therapeutics. It was presented at the ISN Nexus Symposium 2014 taking place in Brisbane, Australia on September 25-28, 2014 for which the theme was ‘Hypertension and the Kidney’.

Thursday, 28 July 2016 22:27

A Modern View of Renal Regulation

This presentation was given by Armin Kurtz from the Institute of Physiology at the University of Regensburg, Germany. It was presented at the ISN Nexus Symposium 2014 taking place in Brisbane, Australia on September 25-28, 2014 for which the theme was ‘Hypertension and the Kidney’.

This presentation was given by Toshio Miyata from Tohoku University Graduate School of Medicine in Japan. It was given during the ISN Nexus Symposium 2014 held in Bergamo, Italy on April 3-6, 2014. The focus this year was on the New era of drug discovery and clinical trials in kidney disease.

Assistindo a esse webinar, você discutirá o papel do rim nas complicações do diabetes, identificará os principais objetivos do tratamento de pacientes com diabetes e DRC, apresentará as atuais diretrizes sobre como tratar as complicações do diabetes em pacientes com DRC.

This webinar aims to:

  1. Understand the medical benefits of more frequent hemodialysis.

  2. Identify prescription options available to patients.

  3. Understand and learn how to prescribe the low dialysis volume high efficiency approach to dialysis therapy. 

  4. Recognize potential complications as well as measures to prevent their occurrence.

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact